scholarly journals Intensity Modulated Radiotherapy is an Effective Treatment for Basosquamous Cell Cancer

2015 ◽  
Vol 22 (1) ◽  
pp. 53-58
Author(s):  
Rolina K. Al-Wassia

Basosquamous cell carcinoma is an uncommon skin cancer with an incidence rate between 1.5% and 2.7%. Surgical excision is the therapy of choice for most skin neoplasm. Depending on the tumor presentation size, location, and patient general condition, there are complementary approaches available: radiation therapy, for curative intent or used as an alternative to maximize local control and symptomatic relief. The case is a 54-year-old male with a seventeen year history of six times recurrent Basosquamous cell cancer that started as a skin nodule on the left nasolabial fold and ended with a mass penetrating into the left ethmoid sinus and orbital cavity. The patient was then treated using intensity modulated radiotherapy as the only effective second alternative modality after debulking surgery. Radiation intent was curative, aiming for eradication of the tumor, maximizing the local control and relief of symptoms. The follow-up demonstrated an eighty percent tumor shrinkage as measured on imaging studies in addition to an excellent cosmetic outcome. Intensity modulated radiotherapy proved to be an efficient treatment modality, with acceptable toxicity and excellent local control, when the patient did not prefer the surgical option for the cosmetic compromise.  

2021 ◽  
Author(s):  
Liqing Li ◽  
Ying Zhou ◽  
Yong Huang ◽  
Ping Liang ◽  
Shixiong Liang ◽  
...  

Abstract Background: It is unclear whether robotic stereotactic body radiotherapy (SBRT) is superior to intensity-modulated radiotherapy (IMRT) in advanced hepatocellular carcinoma (HCC). This study aimed to compare the long-term outcomes of SBRT with those of IMRT in HCCs with portal vein tumor thrombosis (PVTT). Methods: We retrospectively evaluated 287 HCC patients with PVTT who underwent radiotherapy between January 2000 and January 2017. Of them, 154 and 133 patients were treated with IMRT and SBRT, respectively. Overall survival (OS), progression-free survival (PFS), intrahepatic control (IC), and local control (LC) were evaluated in univariable and propensity-score matched analyses. Results: After matching, 102 well-paired patients were selected. There was no significant difference in the 6-, 12-, 24-, and 60-month cumulative OS (73.5, 42.9, 23.6, 7.6% vs. 72.4, 45.1, 29.8, 13.2%, P=0.151), PFS (53.9, 29.3, 21.8, 7.5% vs. 54.5, 19.3, 12.0, 9.6%, P=0.744) , IC (61.4, 45.7, 39.0, 26.8% vs. 75.1, 45.8, 35.9, 28.7%, P=0.144), and LC (85.2, 56.5, 52.1, 47.4% vs. 87.4, 65.2, 62.1, 62.1%, P=0.191) between the IMRT and SBRT groups. A biologically effective dose assumed at an a/b ratio of 10 (BED10) of ≥100 Gy was the optimal cutoff for predicting the OS, PFS, IC, and LC in the patients who received SBRT. Conclusions: When high-precision tracking technology is available, SBRT appears to be a safe and more time-efficient treatment, achieving comparable OS, PFS, IC and LC to IMRT for local advanced HCC with PVTT. A BED10≥100 Gy is recommended if tolerated by normal tissue.


2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 599-599
Author(s):  
Yuanyuan Zhang ◽  
Jonathan Schoenhals ◽  
Alana Christie ◽  
Chiachien Wang ◽  
Osama Mohamad ◽  
...  

599 Background: Stereotactic ablative radiotherapy (SAbR) is a standard of care for treating renal cell cancer (RCC) cranial metastasis. We describe the effect of SAbR on oligometastatic extra-cranial RCC disease course. Methods: We retrospectively reviewed 49 patients with oligometastatic RCC with 68 extra-cranial lesions. Patients were treated with SAbR with a curative intent from 2007 to 2017. We analyzed local control, systemic therapy free survival (mPFS), and overall survival. Results: With a median follow-up of 28 months (IQR: 16.0-40.3), the 1-year and 2-year overall survival after SAbR was 93.4% (95% CI: 81.0-97.8), and 83% (95% CI: 67.4-91.5) respectively. The median overall survival was not reached. The median time to systemic therapy was 13.4 months from the first SAbR(95% CI: 8.8-27.6). Median times from the first SabR course to second and third line systemic therapy (or death) were 31.8 months and 45 months, respectively. Patients in the favorable risk group by the Heng’s criteria (HR = 8.67, p = 0.04), with nometastatic disease at diagnosis (HR = 10.38, p < 0.01) and with clear cell histology (HR = 6.15, p < 0.01) exhibited better survival, as shown by univariate analysis. Patients with no metastatic disease at diagnosis (HR = 2.56, p = 0.02) and only one metastasis treated with SAbR (HR = 2.36, p = 0.03) also exhibited better systemic therapy-free survival. SAbR had an excellent local control rate of 94% at 2 years with no reported grade 3 or higher toxicity. Conclusions: SAbR is an effective and safe treatment for oligometastatic RCC, offering excellent local control with minimal toxicity. SAbR delayed the start of systemic therapy for this RCC cohort, offering quality of life benefits for patients without adversely affecting the progression on subsequent lines of systemic therapy. These findings call for prospective verification.


2009 ◽  
Vol 73 (1) ◽  
pp. 173-177 ◽  
Author(s):  
Amarinthia E. Curtis ◽  
M. Fatih Okcu ◽  
Murali Chintagumpala ◽  
Bin S. Teh ◽  
Arnold C. Paulino

Sign in / Sign up

Export Citation Format

Share Document